MORE effective treatments for one of the deadliest forms of cancer are one step closer thanks to groundbreaking research conducted by the University of Sheffield.
Scientists from the Universities of Sheffield and Cologne have identified the dependencies of multiple Small Cell Lung Cancer (SCLC) types – paving the way for clinical trials of new targeted treatments which could revolutionise the current approach.
Around 40,000 people are diagnosed annually with lung cancer in the UK, and SCLC accounts for nearly one in five of all these cases.
Unfortunately, the prognosis for SCLC patients is very bleak and two thirds of patients die within five years.
Dr Patrick Eyers, from the University of Sheffield’s Institute for Cancer Studies, said new clinical trials would show whether or not patients with SCLC cells could be treated a different approach.